Abstract
OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and c......
小提示:本篇文献需要登录阅读全文,点击跳转登录